Resistance and intolerance to statins

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 10, 2014, Pages 1057-1066

  Reiner, Z ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Ezetimibe; Intolerance; LDL cholesterol; PCSK9; Resistance; Statins

Indexed keywords

ALIROCUMAB; AMIODARONE; APOLIPOPROTEIN E; BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; EZETIMIBE; FARNESOID X RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; MULTIDRUG RESISTANCE PROTEIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; THYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN; AZETIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BILE ACID; HYPOCHOLESTEROLEMIC AGENT;

DNA POLYMORPHISM; DRUG ABSORPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSPORT; DYSLIPIDEMIA; ENZYME ACTIVITY; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPOTHYROIDISM; LIPID METABOLISM; MYOPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; DRUG COMBINATION; DRUG RESISTANCE; DRUG TOLERANCE; GENETIC POLYMORPHISM; GENETICS; HYPERCHOLESTEROLEMIA; PHARMACOGENETICS;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; BENZIMIDAZOLES; BILE ACIDS AND SALTS; CHOLESTEROL, LDL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84908505976     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.05.009     Document Type: Review

References (83)

1. Graham I., Cooney M.T., Bradley D., Dudina A., Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep 2012, 14:709-720.
2. Reiner Ž., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
3. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 10.1016/j.jacc.2013.11.002.
4. Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464.
5. Reiner Ž., Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J 2013, 54:339-345.
6. Reiner Ž., De Bacquer D., Kotseva K., Prugger C., De Backer G., Wood D. EUROASPIRE III study group. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis 2013, 231:300-307.
7. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
8. Ray K.K., Kastelein J.J., Matthijs Boekholdt S., Nicholls S.J., Khaw K.T., Ballantyne C.M., et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014, 25:960-968.
9. Krauss R.M., Mangravite L.M., Smith J.D., Medina M.W., Wang D., Guo X., et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008, 117:1537-1544.
10. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton V.P., Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. J Am Med Assoc 2004, 291:2821-2827.
11. Thompson J.F., Man M., Johnson K.J., Wood L.S., Lira M.E., Lloyd D.B., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005, 5:352-358.
12. Thompson J.F., Hyde C.L., Wood L.S., Paciga S.A., Hinds D.A., Cox D.R., et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet 2009, 2:173-181.
13. Donnelly L.A., Doney A.S., Dannfald J., Whitley A.L., Lang C.C., Morris A.D., et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008, 18:1021-1026.
14. Polisecki E., Muallem H., Maeda N., Peter I., Robertson M., McMahon A.D., et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008, 200:109-114.
15. Rebecchi I.M., Rodrigues A.C., Arazi S.S., Genvigir F.D., Willrich M.A., Hirata M.H., et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol 2009, 77:66-75.
16. Knauer M.J., Urquhart B.L., Meyer zu Schwabedissen H.E., Schwarz U.I., Lemke C.J., Leake B.F., et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010, 106:297-306.
17. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004, 93:1046-1050.
18. Bernsdorf A., Giessmann T., Modess C., Wegner D., Igelbrink S., Hecker U., et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006, 61:440-450.
19. Mega J.L., Morrow D.A., Brown A., Cannon C.P., Sabatine M.S. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009, 29:1310-1315.
20. Voora D., Shah S.H., Reed C.R., Zhai J., Crosslin D.R., Messer C., et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008, 1:100-106.
21. Generaux G.T., Bonomo F.M., Johnson M., Doan K.M. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 2011, 41:639-651.
22. Niemi M., Schaeffeler E., Lang T., Fromm M.F., Neuvonen M., Kyrklund C., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004, 14:429-440.
23. Rodrigues A.C., Perin P.M., Purim S.G., Silbiger V.N., Genvigir F.D., Willrich M.A., et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011, 12:5815-5827.
24. Takane H., Miyata M., Burioka N., Shigemasa C., Shimizu E., Otsubo K., et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006, 51:822-826.
25. Medina M.W., Theusch E., Naidoo D., Bauzon F., Stevens K., Mangravite L.M., et al. RHOA is a modulator of the cholesterol-lowering effects of statin. PLoS Genet 2012, 8:e1003058.
26. Chan D.C., Watts G.F., Wang J., Hegele R.A., van Bockxmeer F.M., Barrett P.H. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clin Endocrinol (Oxf) 2008, 69:45-51.
27. Polisecki E., Peter I., Simon J.S., Hegele R.A., Robertson M., Ford I., et al. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J Lipid Res 2010, 51:1201-1207.
28. Hu M., Lui S.S., Tam L.S., Li E.K., Tomlinson B. The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin. J Lipid Res 2012, 53:1384-1389.
29. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 2005, 180:407-415.
30. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., Rodriguez C., Park J.S., Cole T., et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157-166.
31. Hubacek J.A., Vrablik M. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact 2011, 26:13-20.
32. Deshmukh H.A. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res 2012, 53:1000-1011.
33. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26:1094-1100.
34. Humphries S.E., Whittall R.A., Hubbart C.S., Maplebeck S., Cooper J.A., Soutar A.K., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43:943-949.
35. Dong B., Wu M., Li H., Kraemer F.B., Adeli K., Seidah N.G., et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010, 51:1486-1495.
36. Salazar L.A., Hirata M.H., Quintão E.C., Hirata R.D. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000, 14:125-131.
37. Chasman D.I., Giulianini F., MacFadyen J., Barratt B.J., Nyberg F., Ridker P.M. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012, 5:257-264.
38. Miltiadous G., Xenophontos S., Bairaktari E., Ganotakis M., Cariolou M., Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics 2005, 15:219-225.
39. Donnelly L.A., van Zuydam N.R., Zhou K., Tavendale R., Carr F., Maitland-van der Zee A.H., et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet Genomics 2013, 23:518-525.
40. Hannuksela M.L., Liinamaa M.J., Kesäniemi Y.A., Savolainen M.J. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994, 110:35-44.
41. Boekholdt S.M., Sacks F.M., Jukema J.W., Shepherd J., Freeman D.J., McMahon A.D., et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005, 111:278-287.
42. de Keyser C.E., Eijgelsheim M., Hofman A., Sijbrands E.J., Maitland-van der Zee A.H., van Duijn C.M., et al. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. Pharmacogenomics J 2011, 11:72-80.
43. Takahashi T., Takahashi K., Yamashina M., Maesawa C., Kajiwara T., Taneichi H., et al. Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects. Diabetes Care 2010, 33:463-466.
44. Vrablík M., Hubáček J.A., Dlouhá D., Lánská V., Rynekrová J., Zlatohlávek L., et al. Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res 2012, 61:609-617.
45. Hopewell J.C., Parish S., Offer A., Link E., Clarke R., Lathrop M., et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J 2013, 34:982-992.
46. van der Baan F.H., Knol M.J., Maitland-van der Zee A.H., Regieli J.J., van Iperen E.P., Egberts A.C., et al. Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. Pharmacogenomics J 2013, 13:318-324.
47. Simon J.A., Lin F., Hulley S.B., Blanche P.J., Waters D., Shiboski S., et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (CAP) Study. Am J Cardiol 2006, 97:843-850.
48. Y1 Chen, Ku H., Zhao L., Wheeler D.C., Li L.C., Li Q., et al. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation. Arterioscler Thromb Vasc Biol 2014, 34:365-376.
49. Boccara F., Simon T., Lacombe K., Cohen A., Laloux B., Bozec E., et al. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. AIDS 2006, 20:2395-2398.
50. Johns K.W., Bennett M.T., Bondy G.P. Are HIV positive patients resistant to statin therapy?. Lipids Health Dis 2007, 6:27.
51. Al-Sarraf A., Li M., Frohlich J. Statin resistant dyslipidemia in a patient treated with amiodarone. BMJ Case Rep 2011, 10.1136/bcr.08.2011.4620.
52. Kaddurah-Daouk R., Baillie R.A., Zhu H., Zeng Z.B., Wiest M.M., Nguyen U.T., et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 2010, 6:191-201.
53. Trupp M., Zhu H., Wikoff W.R., Baillie R.A., Zeng Z.B., Karp P.D., et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One 2012, 7:e38386.
54. Bell K.J., Kirby A., Hayen A., Irwig L., Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. Br Med J 2011, 342. d12.
55. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. J Am Med Assoc 2002, 288:462-467.
56. Mann D.M., Woodward M., Muntner P., Falzon L., Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010, 44:1410-1421.
57. Simpson R.J., Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010, 4:462-471.
58. Reiner Ž Sonicki Z., Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med 2010, 51:494-496.
59. Bergman Marković B., Kranjčević K., Reiner Ž., Milaković Blažeković S., Stojanović Špehar S. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croat Med J 2005, 46:944-989.
60. Reiner Ž., Sonicki Z., Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010, 213:598-603.
61. Reiner Ž., Sonicki Z., Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat Med J 2012, 53:278-284.
62. Mampuya W.M., Frid D., Rocco M., Huang J., Brennan D.M., Hazen S.L., et al. Treatment strategies in patients with statin intolerance: the cleveland clinic experience. Am Heart J 2013, 166:597-603.
63. Abd T.T., Jacobson T.A. Statin induced myopathy: a review and update. Expert Opin Drug Saf 2011, 10:373-387.
64. Carr D.F., O'Meara H., Jorgensen A.L., Campbell J., Hobbs M., McCann G., et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 2013, 94:695-701.
65. Egan A., Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011, 365:285-287.
66. Mancini G.B., Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011, 27:635-662.
67. Riphagen I.J., van der Veer E., Muskiet F.A., DeJongste M.J. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012, 28:1247-1252.
68. Argo C.K., Loria P., Caldwell S.H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology 2008, 48:662-669.
69. Oni E.T., Sinha P., Karim A., Martin S.S., Blaha M.J., Agatston A.S., et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res 2014, 45:52-57.
70. Younoszai Z., Li Z., Stepanova M., Erario M., Cable R., Younossi Z.M. Statin use is not associated with liver related mortality. Ann Hepatol 2013, 13:84-90.
71. Tikkanen M.J., Fayyad R., Faergeman O., Olsson A.G., Wun C.C., Laskey R., et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013, 168:3846-3852.
72. Gotto A.M., Moon J.E. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol 2013, 10:560-570.
73. Reiner Ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis 2013, 23:799-807.
74. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010, 24:19-28.
75. Wierzbicki A.S., Doherty E., Lumb P.J., Chik G., Crook M.A. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005, 21:333-338.
76. Xydakis A.M., Guyton J.R., Chiou P., Stein J.L., Jones P.H., Ballantyne C.M. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004, 94:795-797.
77. Lakoski S.G., Xu F., Vega G.L., Grundy S.M., Chandalia M., Lam C., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 2010, 95:800-809.
78. Becker D.J., Gordon R.Y., Halbert S.C., French B., Morris P.B., Rader D.J. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830-839.
79. Stein E.A., Dufour R., Gagne C., Gaudet D., East C., Donovan J.M., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292.
80. Thomas G.S., Cromwell W.C., Ali S., Chin W., Flaim J.D., Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013, 62:2178-2184.
81. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
82. Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
83. Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Langslet G., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243.